Ramipril
- Generic Name
- Ramipril
- Brand Names
- Altace, Altace HCT
- Drug Type
- Small Molecule
- Chemical Formula
- C23H32N2O5
- CAS Number
- 87333-19-5
- Unique Ingredient Identifier
- L35JN3I7SJ
- Background
Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure...
- Indication
For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high ...
- Associated Conditions
- Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hearth Failure With Reduced Ejection Fraction (HFrEF), Hypertension, Myocardial Infarction, Nondiabetic proteinuric chronic kidney disease, Stroke, High risk cardiovascular event
- Associated Therapies
- -
Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab
- Conditions
- Interventions
- First Posted Date
- 2014-09-11
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Azienda Ospedaliero-Universitaria Careggi
- Target Recruit Count
- 262
- Registration Number
- NCT02236806
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Careggi, Florence University, Florence, Italy
Steady State Pharmacokinetics of Telmisartan, Ramipril or the Combination Following Repeated Oral Doses to Healthy Male and Female Volunteers
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 42
- Registration Number
- NCT02215005
Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD
- Conditions
- Interventions
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Cardiology Research UBC
- Target Recruit Count
- 18
- Registration Number
- NCT02008786
- Locations
- 🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada
Aliskiren Study of Safety and Efficacy in Senior Hypertensives
- Conditions
- Interventions
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01922141
Ramipril for the Treatment of Oligospermia
- Conditions
- Interventions
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 2
- Registration Number
- NCT01856361
- Locations
- 🇺🇸
Weill Cornell Medical College, Department of Urology, New York, New York, United States
Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- AHEPA University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT01743014
- Locations
- 🇬🇷
Aristotle University of Thessaloniki/ AHEPA University Hospital, Thessaloniki, Greece
🇬🇷AHEPA University Hospital, Thessaloniki, Greece
FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients
- Conditions
- Interventions
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- Gulhane School of Medicine
- Target Recruit Count
- 78
- Registration Number
- NCT01703234
- Locations
- 🇹🇷
Gulhane School of Medicine, Ankara, Turkey
Cardiac Energetics and Function in Normal Human Ageing
- Conditions
- Interventions
- First Posted Date
- 2012-01-05
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
- Target Recruit Count
- 135
- Registration Number
- NCT01504828
- Locations
- 🇬🇧
Campus for Ageing and Vitality, Newcastle upon Tyne, United Kingdom
Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome
- Conditions
- Interventions
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2020-06-17
- Target Recruit Count
- 66
- Registration Number
- NCT01485978
- Locations
- 🇩🇪
University Medical Center Goettingen, Goettingen, Germany
An Open-labeled Trial of Ramipril in Patients With Migraine
- First Posted Date
- 2011-07-26
- Last Posted Date
- 2011-08-08
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT01402479
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.